Compare ADMA Biologics Inc (ADMA) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Lumen Technologies Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Lumen Technologies Inc trades at $6.56 (market cap $6.64B). The key difference: Lumen Technologies Inc is far larger — about 3.1× ADMA Biologics Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | LUMN | |
|---|---|---|
Market Cap | $2.13B | $6.64B |
Sector | Health | Media |
52-Week High | $20.38 | $11.83 |
52-Week Low | $7.60 | $3.70 |
Enterprise Value | $2.20B | $18.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
LUMN trades at $6.44, up 0.16% on the day, with a bearish technical signal but bullish oscillators. The company reported a net loss of $1.74B in 2025, though it beat EPS estimates in two of the last three quarters. Recent news highlights the completion of the Alkira acquisition, aimed at boosting its AI-era networking capabilities. Revenue has declined from $17.5B in 2022 to $12.4B in 2025, with a negative net income margin of -14.34%.
The outlook remains challenging due to persistent losses and high debt, but strategic acquisitions and a 15% forward free cash flow yield offer potential upside. Risks include execution hurdles in integrating acquisitions and intense telecom competition. Analyst consensus is a Hold with a $8.25 price target, suggesting cautious optimism amid fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
